Dr. Broaddus is a Professor with tenure in the Department of Pathology at the University of Texas M.D. Anderson Cancer Center.  He is one of two Principal Investigators for the NCI-funded Endometrial Cancer Sponsored Program of Research Excellence (SPORE) at MD Anderson, leading one project and the pathology core.  He has authored 220 manuscripts in peer-reviewed journals.  Much of his research is focused on endometrial cancer, especially molecular mechanisms of pathogenesis, molecular diagnostics, and clinical pathology laboratory assays for the identification of women with Lynch Syndrome.  He has been awarded the John P. McGovern Outstanding Teacher Award twice (2005-2006 and 2016-2017) from the MD Anderson Cancer Center/UT Health Graduate School of Biomedical Sciences.

Endometrial cancer is the most common gynecological cancer in the Western Hemisphere.  In contrast to many other cancer types, both the incidence and mortality from endometrial cancer are increasing.  Pathologists have traditionally been important drivers of the clinical care of endometrial cancer.  Pathology parameters, such as determining endometrioid vs. non-endometrioid histotype, depth of myometrial invasion, and tumor stage directly impact the subsequent therapeutic approach for these patients.  Recent genomically-derived data suggest that incorporation of molecular diagnostics into the routine pathologic analysis of endometrial cancers can help to identify important prognostic information that can also help to inform therapeutic decision-making.  Such molecular diagnostics help to highlight the clinically-relevant diversity of endometrial cancers, especially those of the endometrioid subtype.